| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 790.11M | 790.11M | 720.63M | 741.05M | 735.34M | 656.23M |
| Gross Profit | 310.60M | 300.64M | 282.00M | 285.10M | 269.95M | 241.26M |
| EBITDA | 118.75M | 128.18M | 121.92M | 191.45M | 116.63M | 91.98M |
| Net Income | 55.76M | 55.76M | 73.07M | 138.99M | 61.39M | 36.47M |
Balance Sheet | ||||||
| Total Assets | 1.57B | 1.57B | 1.01B | 1.02B | 934.44M | 962.22M |
| Cash, Cash Equivalents and Short-Term Investments | 104.54M | 104.54M | 154.20M | 195.71M | 104.84M | 136.37M |
| Total Debt | 603.70M | 592.57M | 187.89M | 199.22M | 214.08M | 228.53M |
| Total Liabilities | 827.29M | 827.29M | 383.55M | 417.48M | 435.10M | 455.80M |
| Stockholders Equity | 711.68M | 711.68M | 621.50M | 607.45M | 499.34M | 506.43M |
Cash Flow | ||||||
| Free Cash Flow | 61.06M | 41.25M | 72.36M | 66.53M | 53.83M | 61.83M |
| Operating Cash Flow | 69.64M | 69.60M | 92.66M | 90.80M | 77.72M | 83.58M |
| Investing Cash Flow | -503.43M | -503.43M | -61.63M | 41.56M | -31.04M | -39.09M |
| Financing Cash Flow | 380.49M | 380.49M | -69.20M | -40.04M | -69.43M | -31.73M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $2.20B | 24.43 | 22.47% | 0.10% | 4.65% | 8.81% | |
| ― | $2.93B | 52.29 | 8.37% | 0.52% | 9.64% | -24.68% | |
| ― | $1.91B | 54.90 | 3.93% | 0.63% | -5.41% | 17.47% | |
| ― | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
| ― | $2.22B | ― | -1.50% | 2.87% | -7.93% | 91.44% | |
| ― | $2.53B | ― | -21.02% | ― | 20.19% | -12.34% | |
| ― | $1.88B | -2.22 | -28.31% | ― | 14.40% | -662.25% |
Standex International Corporation is a diversified multi-industry manufacturer operating in five sectors: Electronics, Engineering Technologies, Scientific, Engraving, and Specialty Solutions, with a global presence in countries such as the United States, Europe, and China.
Standex International’s latest earnings call painted a picture of both achievement and challenge. The company celebrated significant milestones in profit generation, segment growth, and new product development, setting a positive tone for fiscal 2026. However, the discussion also acknowledged hurdles such as a decline in organic revenue, difficulties within the Scientific segment, and pressures from debt, which tempered the overall optimism.